Vimseltinib
- Generic Name
- Vimseltinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H25N7O2
- CAS Number
- 1628606-05-2
- Unique Ingredient Identifier
- PX9FTM69BF
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 36
- Registration Number
- NCT06619561
- Locations
- ๐บ๐ธ
Cleveland Clinic, Cleveland, Ohio, United States
๐บ๐ธCity of Hope National Medical Center, Duarte, California, United States
๐บ๐ธAvera Cancer Institute, Sioux Falls, South Dakota, United States
Study of Vimseltinib for Tenosynovial Giant Cell Tumor
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-09-28
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 120
- Registration Number
- NCT05059262
- Locations
- ๐ช๐ธ
Hospital Universitario Vall d'Hebron, Barcelona, Spain
๐บ๐ธOhio State University, Columbus, Ohio, United States
๐บ๐ธUniversity of Colorado, Aurora, Colorado, United States
Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2017-03-03
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 120
- Registration Number
- NCT03069469
- Locations
- ๐บ๐ธ
Stanford Cancer Institute, Palo Alto, California, United States
๐บ๐ธMSKCC, New York, New York, United States
๐ฆ๐บPeter MacCallum Cancer Centre, Melbourne, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2024. All Rights Reserved by MedPath